PMID- 32194171
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20240404
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Print)
IS  - 0168-3659 (Linking)
VI  - 322
DP  - 2020 Jun 10
TI  - Renal clearable nanocarriers: Overcoming the physiological barriers for precise 
      drug delivery and clearance.
PG  - 64-80
LID - S0168-3659(20)30172-3 [pii]
LID - 10.1016/j.jconrel.2020.03.020 [doi]
AB  - Physiological barriers encountered in the clinical translation of cancer 
      nanomedicines inspire the community to more deeply understand nano-bio 
      interactions in not only tumor microenvironment but also entire body and develop 
      new nanocarriers to tackle these barriers. Renal clearable nanocarriers are one 
      kind of these newly emerged drug delivery systems (DDSs), which enable drugs to 
      rapidly penetrate into the tumor cores with no need of long blood retention and 
      escape macrophage uptake in the meantime they can also enhance body elimination 
      of non-targeted anticancer drugs. As a result, they can improve therapeutic 
      efficacies and reduce side effects of anticancer drugs. Not limited to anticancer 
      drugs, diagnostic agents can also be achieved with these renal clearable DDSs, 
      which might also be applied to improve the precision in the gene editing and 
      immunotherapy in the future.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Peng, Chuanqi
AU  - Peng C
AD  - Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 
      West Campbell Road, Richardson, TX 75080, USA.
FAU - Huang, Yingyu
AU  - Huang Y
AD  - Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 
      West Campbell Road, Richardson, TX 75080, USA.
FAU - Zheng, Jie
AU  - Zheng J
AD  - Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 
      West Campbell Road, Richardson, TX 75080, USA. Electronic address: 
      jiezheng@utdallas.edu.
LA  - eng
GR  - R01 DK103363/DK/NIDDK NIH HHS/United States
GR  - R01 DK115986/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200316
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Carriers)
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - *Antineoplastic Agents/therapeutic use
MH  - Drug Carriers/therapeutic use
MH  - Drug Delivery Systems
MH  - Humans
MH  - Nanomedicine
MH  - *Nanoparticles
MH  - *Neoplasms/drug therapy
MH  - *Pharmaceutical Preparations
MH  - Tumor Microenvironment
PMC - PMC8696951
MID - NIHMS1761394
OTO - NOTNLM
OT  - Cancer
OT  - Drug delivery
OT  - Nanocarriers
OT  - Nanomedicine
OT  - Nanoparticle
OT  - Physiological barriers
OT  - Renal clearance
COIS- Declaration of Competing Interest The authors declare no competing financial 
      interest.
EDAT- 2020/03/21 06:00
MHDA- 2021/06/22 06:00
PMCR- 2021/12/23
CRDT- 2020/03/21 06:00
PHST- 2019/12/15 00:00 [received]
PHST- 2020/02/27 00:00 [revised]
PHST- 2020/03/15 00:00 [accepted]
PHST- 2020/03/21 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/03/21 06:00 [entrez]
PHST- 2021/12/23 00:00 [pmc-release]
AID - S0168-3659(20)30172-3 [pii]
AID - 10.1016/j.jconrel.2020.03.020 [doi]
PST - ppublish
SO  - J Control Release. 2020 Jun 10;322:64-80. doi: 10.1016/j.jconrel.2020.03.020. 
      Epub 2020 Mar 16.